PLEDPHARMA PRESENTS NEW IN-DEPTH FOLLOW-UP DATA FROM PLIANT

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
PLEDPHARMA PRESENTS NEW IN-DEPTH FOLLOW-UP DATA FROM PLIANT STUDY - PLEDOX® SHOWN TO REDUCE CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY BY 75 PERCENT

Stockholm, 2015-12-01 08:30 CET (GLOBE NEWSWIRE) --  

Earlier this year, PledPharma presented results from PLIANT showing that PledOx ® reduces the appearance of nerve damage symptoms by 43 percent compared to placebo during treatment . These results were based on the treating doctor's assessment of the severity of the symptoms. However, the long-term data now being presented are based on the patients' own assessments of symptoms and show that the effect of pretreatment with PledOx ® is even more pronounced at 24 weeks post treatment .

Treatment by PledOx ® with a 5 µmol / kg dose was found to keep the symptoms stable at a low level during the first 24 weeks after completion of treatment, while the placebo group showed increased neuropathy. Patients in this dosage group estimated the magnitude of neuropathy to be 62 percent lower than patients in the placebo group at week 12, and 75 percent lower at 24 weeks after completion of chemotherapy. The difference is statistically significant (p<0.01 at 24 weeks and p<0.05 at 12 weeks). For the group receiving the placebo the incidence and severity of symptoms increased significantly until week 12 and then levelled out at a high level.

"These new and more detailed long-term results from PLIANT study increase the possibility of establishing PledOx ® as a future standard treatment to avoid permanent nerve damage due to cytotoxic therapy in colorectal cancer. This can lead to more effective cancer treatment and a better quality of life for these long-suffering patients", said CEO Jacques Näsström. A detailed presentation of the above results is provided on the PledPharma webpage. A recording of the presentation on Redeye Investor Forum will be available on Redeye website, www.redeye.se

FOR FURTHER INFORMATION, PLEASE CONTACT:

Jacques Näsström, CEO PledPharma AB

Phone: +46 73-713 09 79

E-mail: jacques.nasstrom@pledpharma.se

ABOUT THE STUDY PLIANT is a randomized double-blinded placebo-controlled phase IIb study with three parallel groups in which patients with advanced colorectal cancer received FOLFOX6 chemotherapy for up to eight treatment cycles and either PledOx ® at a dose of 2 µmol/kg, 5 µmol/kg or placebo (a small portion of the patients were treated with 10 µmol/kg). The study was conducted at about thirty centres in Europe and the US, and included a total of 173 patients. The purpose of this study was to investigate whether pre-treatment with PledOx ® decreased the frequency and severity of side effects related to FOLFOX6 treatment. The primary endpoint was the incidence of neuropathy (sensory disturbances), which was evaluated every two weeks during the first 16 weeks. The incidence of neuropathy was evaluated using three testing methods - Oxaliplatin Sanofi Specific Scale, Cold Allodynia Test and Leonard Questionnaire. The Cold Allodynia Test and Leonard Questionnaire were also used during the follow-up phase. In the Leonard Questionnaire, patients reporting include among other questions the incidence and intensity of tingling (pins and needles), pain triggered by cold and numbness in hands or feet respectively, on a scale from zero to five. Secondary endpoints included changes in the number of neutrophil granulocytes (a type of white blood cells) and thrombocytes (platelets). In addition, the patients were monitored to ensure that PledOx ® treatment did not decrease the effect of the chemotherapy. FOLFOX is a very commonly used combination of the drugs folinic acid, 5-fluorouracil and oxaliplatin.

ABOUT PLEDOX ® PledOx ® is developed to prevent nerve damage caused by chemotherapy in cancer treatment. The active ingredient calmangafodipir is a New Chemical Entity (NCE) and has been shown to protect human cells against oxidative stress; a condition caused by formation of reactive oxygen and nitrogen compounds during e.g. chemotherapy. Oxidative stress may, among other things, cause damage to the sensory nerves (neuropathy). PledOx ® mimics the endogenous enzyme MnSOD, which represents the cell's intrinsic protection against oxidative stress.

ABOUT NERVE DAMAGE CAUSED BY CHEMOTHERAPY IN COLORECTAL CANCER A large proportion of the patients undergoing treatment with the chemotherapy oxaliplatin, one of the components in FOLFOX, are bothered by symptoms (tingling, pain triggered by cold or numbness in the hands or feet) caused by nerve damage incurred in connection with cytotoxic therapy. After completion of treatment, it is common for these symptoms to persist and for the symptoms to worsen. This adverse reaction leads to that approximately 40 percent of patients need to reduce the chemotherapy dose during treatment and is the most common reason that cancer treatment with oxaliplatin has to be stopped early. This is a reversible problem for most patients, however, about 15-20 percent of patients experience a persistent problem that lasts a long time after end of treatment. Today there is no cure for neuropathy available.

ABOUT PLEDPHARMA PledPharma develops new drugs that protect the body against oxidative stress – a condition that can be caused by chemotherapy and acetaminophen (paracetamol) poisoning. The company's most advanced project PledOx ® reduces nerve damage associated with chemotherapy. The drug candidate Aladote™ is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. The project PP-099 seeks to limit the damage that occurs to the heart muscle during myocardial infarction. PledPharma’s drug candidates are based on the further development of a substance that, for completely different purposes, already has been used by more than 200 000 patients. This may limit the development risk and simplify the approval process. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bankaktiebolag is the company’s Certified Adviser (phone: +46 8-463 80 00). For more information, see www.pledpharma.se

PledPharma AB discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 129

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 146

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading
New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 139

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 103

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 254

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 66

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 35

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 50

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading

Top 5 Most Recently Viewed Articles

Citi Raises Price Target for Blackstone Amid Encouraging Outlook

Updated Category News Views 131

Citi's Updated Outlook on Blackstone Recently, Citi revisited its financial forecast for The Blackstone Group (NYSE: BX), adjusting the price target upward from $157.00 to $170.00 while maintaining a Neutral stance on the stock. This update follows the company's impressive third-quarter performance, which saw Blackstone's stock rise by 6.3% post-earnings announcement....

Continue Reading
JAB's Strategic Acquisition of Mondelez Shares in JDE Peet's

Updated Category News Views 92

JAB's Significant Move in the Coffee Industry In a strategic and noteworthy development, JAB has made headlines by agreeing to acquire a substantial share package from Mondelez, focusing on Dutch coffee giant JDE Peet's. This major transaction amounts to approximately €2.2 billion, or about $2.4 billion. JAB intends to purchase 86 million shares at a price of €25.10...

Continue Reading
Urgent Update for DXC Technology Company Investors

Updated Category News Views 272

DXC Technology Company (NYSE: DXC) found itself in hot water back in 2024 when shareholders raised hell over alleged falsehoods that inflated stock prices. The Rosen Law Firm rolled out a class action lawsuit aimed at those who bought shares during what they dubbed the Class Period—a time rife with questionable operational claims from DXC's brass. Allegations Surface:...

Continue Reading
Investigation Launched: National Grid Faces Legal Scrutiny

Updated Category News Views 283

Bragar Eagel & Squire, P.C. Initiates Investigation Bragar Eagel & Squire, P.C., a well-regarded law firm known for advocating for investors, has begun an investigation surrounding concerns related to National Grid plc (NYSE: NGG). This inquiry primarily aims to assist stockholders who may have experienced losses while owning shares of National Grid. The firm invites...

Continue Reading
Oil & Gas Sector Trends: Path to 8.79 Trillion Growth

Updated Category News Views 223

Oil & Gas Market Growth and Projections The global oil and gas market has positioned itself for remarkable expansion. With estimates currently valuing the market at approximately USD 6.10 trillion, projections suggest it could soar to around USD 8.79 trillion by 2034. This growth translates to a compound annual growth rate (CAGR) of 3.72% between 2025 and 2034. Notably,...

Continue Reading